Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2011
11/01/2011US8048993 Heparanase specific molecular probes and their use in research and medical applications
11/01/2011US8048918 Treatment of hyperproliferative diseases
11/01/2011US8048890 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents
11/01/2011US8048855 Method for suppressing graft-versus-host-disease
11/01/2011US8048847 Derivatives of the IL-2 receptor gamma chain, their production and use
11/01/2011US8048844 Preventing airway mucus production by administration of EGF-R antagonists
11/01/2011US8048424 Insect poison allergens with reduced IgE reactivity and method for producing the same
11/01/2011CA2476683C Partial and full agonists of a1 adenosine receptors
11/01/2011CA2473461C Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
11/01/2011CA2468254C Therapeutic coating for an intravascular implant
11/01/2011CA2466418C Lipoxin a4 analogs
11/01/2011CA2458534C Phenethanolamine derivatives for treatment of respiratory diseases
11/01/2011CA2452986C Use of polyclonal anti-hiv goat serum as a therapeutic agent
11/01/2011CA2446193C 1,4-disubstituted benzo-fused cycloalkyl urea compounds
11/01/2011CA2409741C Tnf-.alpha. production inhibitors
11/01/2011CA2402489C Oral tolerance induction by collagen to prevent allograft rejection
11/01/2011CA2402247C Biodegradable immunomodulatory formulations and methods for use thereof
11/01/2011CA2396718C Pre-transplant accomodated organs resistant to anti-donor immunity
11/01/2011CA2380947C Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
11/01/2011CA2203622C Compounds, pharmaceutical composition and diagnostic device comprising them and their use
10/2011
10/27/2011WO2011133931A1 Use of il-27 antagonists for treating inflammatory bowel disease
10/27/2011WO2011133734A1 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
10/27/2011WO2011133707A2 Anti-viral compounds
10/27/2011WO2011133105A1 Novel allergen
10/27/2011WO2011132048A1 Heteroaryl compounds as pde10a inhibitors
10/27/2011WO2011131314A1 Combination of drugs with protein-binding prodrugs
10/27/2011WO2011130800A1 Eczema treatment
10/27/2011WO2011068853A3 TREATMENT OF IgE-MEDIATED DISEASE
10/27/2011WO2011039511A3 Agents, uses and methods
10/27/2011WO2011004282A4 Novel polymorphic form of teriflunomide salts
10/27/2011US20110265195 Unique associated kaposi's sarcoma virus sequences and uses thereof
10/27/2011US20110263706 Method for enhancing the dna repair process, treating disorders associated with the dna repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering pruified quinic acid and/or carboxy alkyl ester
10/27/2011US20110263680 Reduced size self-delivering rnai compounds
10/27/2011US20110263661 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators
10/27/2011US20110263649 Crystalline form of lenalidomide and a process for its preparation
10/27/2011US20110263642 Methods for treatment of multiple sclerosis
10/27/2011US20110263632 Solid dispersions comprising tacrolimus
10/27/2011US20110263629 Amides of diazabicyclooctanes and uses thereof
10/27/2011US20110263612 Compounds that modulate intracellular calcium
10/27/2011US20110263610 Compounds and compositions as itpkb inhibitors
10/27/2011US20110263600 Method for preventing or treating a disease related to the glucocorticoid receptor
10/27/2011US20110263594 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
10/27/2011US20110263593 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
10/27/2011US20110263589 Method for preventing or treating a glucocorticoid receptor-related disease
10/27/2011US20110263587 Reversibly heat-gelable aqueous composition
10/27/2011US20110263575 Compounds Useful as Protein Kinase Inhibitors
10/27/2011US20110263571 Novel amide derivative and use thereof as medicine
10/27/2011US20110263555 TGR5 Modulators and Methods of Use Thereof
10/27/2011US20110263541 Kinase inhibitors and their use as pharmaceutical agents
10/27/2011US20110263539 Ship 1 modulator compounds
10/27/2011US20110263532 Halofuginone analogs for inhibition of trna synthetases and uses thereof
10/27/2011US20110263531 Methods for the treatment and amelioration of atopic dermatitis
10/27/2011US20110263526 Nitric Oxide Releasing Prodrugs of Therapeutic Agents
10/27/2011US20110263494 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf-kappab acitivity and use thereof
10/27/2011US20110263492 Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension of dispersion media
10/27/2011US20110263482 Complement inhibitors
10/27/2011US20110263478 Sur1 inhibitors for therapy
10/27/2011US20110263027 Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
10/27/2011US20110262534 polysaccharide capsule enclosing a fatty acid oil-containing emulsion
10/27/2011US20110262529 Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
10/27/2011US20110262527 Cationic lipids and methods of use
10/27/2011US20110262526 Method of inducing an anti-viral immune response
10/27/2011US20110262502 Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
10/27/2011US20110262491 Emulsions and methods of making nanocarriers
10/27/2011US20110262488 Novel HIV-1 Envelope Glycoprotein
10/27/2011US20110262485 Sting (stimulator of interferon genes), a regulator of innate immune responses
10/27/2011US20110262484 Outer membrane vesicle prime-protein boost vaccine
10/27/2011US20110262483 Methods for isolating enveloped virus-based vlps free of infectious agents
10/27/2011US20110262481 High growth reassortant influenza a virus
10/27/2011US20110262480 Method for producing multiple modifications in the chromosome of gram-negative bacteria and salmonella strains which are deficient in c-di-GMP synthesis obtained by said method
10/27/2011US20110262479 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
10/27/2011US20110262478 Recombinant Protein Bodies as Immunogen-Specific Adjuvants
10/27/2011US20110262477 Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
10/27/2011US20110262476 Mutant bacterial glycoproteins and uses thereof
10/27/2011US20110262475 Lyme disease vaccine
10/27/2011US20110262474 Chimeric HIV Antigens
10/27/2011US20110262473 Synthetic vaccine component
10/27/2011US20110262470 Immunoregulatory structures from normally occurring proteins
10/27/2011US20110262469 Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax
10/27/2011US20110262468 Method for Monitoring Vaccine Response Using Single Cell Network Profiling
10/27/2011US20110262461 Biological materials and uses thereof
10/27/2011US20110262457 Modulation of the immune response
10/27/2011US20110262445 Anti-il-12/il-23 antibodies
10/27/2011US20110262441 Method for selective control of helper t cell function
10/27/2011US20110262438 Biological materials related to cxcr7
10/27/2011US20110262435 Il-13 binding agents
10/27/2011US20110262427 Amino acid sequences that modulate the interaction between cells of the immune system
10/27/2011US20110262419 Specifically targeted catalytic antagonists and uses thereof
10/27/2011US20110262408 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
10/27/2011US20110262407 Treatment with alpha7 selective ligands
10/27/2011US20110262394 Dna constructs eliciting immune response against flavivirus and effective adjuvants
10/27/2011US20110262391 Ca9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
10/27/2011US20110262368 C21 thioethers as glucocorticoid receptor agonists
10/27/2011CA2794556A1 Novel allergen
10/26/2011EP2380591A2 Vaccine peptide combinations against cat allergy
10/26/2011EP2380585A1 Methods of treating autoimmune diseases
10/26/2011EP2380580A2 Composition containing extracts of fuscoporia obliqua, ganoderma lucidum and phellinus linteus for promoting the proliferation of hematopoietic stem cells
10/26/2011EP2380578A1 Bioactive agent, pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent
10/26/2011EP2380564A2 An oral pharmaceutical composition
10/26/2011EP2379523A1 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators
1 ... 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 ... 1172